Short Summary
Abbott Diabetes Care Inc.'s IPR challenge against DexCom's glucose monitoring patent was instituted by the PTAB. The Board found a reasonable likelihood of success on anticipation and obviousness grounds over prior art reference Gross, despite acknowledging examination complexity. This decision advances Abbott's efforts to invalidate key claims in the medical device space.
Detailed Summary
The Patent Trial and Appeal Board (PTAB) decided to institute an Inter Partes Review (IPR) petition filed by Abbott Diabetes Care Inc. against DexCom, Inc.'s patent 10709364. The petitioner challenged eight claims based on anticipation and obviousness over the prior art reference Gross US 6,275,717 B1. Although the Board noted technical complexities in the file history that complicated the initial examination, it ultimately determined there was a reasonable likelihood of success for Abbott regarding at least one challenged claim. The petitioner successfully argued that Gross discloses specific limitations related to transcutaneous sensing and predictive calibration functions inherent to glucose monitoring technology.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Abbott Diabetes Care Inc. et al. vs DexCom, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
BESTWAY (USA), INC. et al.vsIntex Marketing Ltd. et al.
Bestway challenged Intex's patent, but the PTAB denied institution because Intex had statutorily disclaimed all claims. The Board also declined to enter an adverse judgment against Intex.
Samsung Electronics Co., Ltd. et al.vsNetlist, Inc.
The PTAB issued a Final Written Decision finding all 30 claims of Netlist’s flash‑DRAM hybrid memory patent unpatentable. Samsung and its co‑petitioners proved the claims were obvious over a combination of Harris, JEDEC FBDIMM standards, Amidi, and Hajeck. The Board’s reasoning hinged on motivation‑to‑combine and claim construction of “memory module.”
Apple Incvs1LSS Inc.
Apple has filed an IPR petition challenging all 11 claims of 1LSS’s magnetic‑wallet patent, asserting that the invention is obvious over a suite of prior‑art references. The petition relies heavily on the Board’s earlier findings and detailed claim‑by‑claim analysis.
Guangzho EKO Trading Development Co., Ltd. (aka EKO Development Ltd.) et al.vsNine Stars Group (U.S.A.) Inc.
The PTAB instituted IPR proceedings against Nine Stars Group (U.S.A.) Inc., finding a reasonable likelihood that claims 1-24 of patent 10822165 are anticipated or obvious over the prior art reference Wang. The Board accepted Petitioner's arguments regarding functional equivalency, particularly concerning 'automatic driving arrangement' and components like the servo motor.
Tempus AI, Inc.vsGuardant Health Inc.
Tempus AI petitions to invalidate Guardant Health’s ’699 patent, asserting that all 27 claims are obvious over Kinde and Miner. The petition emphasizes claim constructions that broaden the scope to circulating cellular DNA and argues discretionary denial is improper.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.